Back to Lung Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00259064

NCT00259064
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with non-small cell lung cancer (NSCLC), confirmed through a tissue or cell sample test
  • Your lung cancer is either at an advanced local stage (Stage IIIB) or has spread to other parts of the body (Stage IV), and cannot be treated with surgery or radiotherapy to cure it
  • You have been assessed as not suitable for chemotherapy
  • Your general health and ability to carry out daily activities falls within a certain range on a standard scale (WHO Performance Status 2 or 3 — confirm with trial site)

Who may not be able to join:

  • You have recently been diagnosed with cancer that has newly spread to the brain or spinal cord
  • It has been less than 4 weeks since you finished radiotherapy, or you are still experiencing side effects from radiotherapy
  • You have another type of cancer in addition to lung cancer
  • Your liver function test results are significantly above the normal range (confirm with trial site)
  • Your white blood cell count or platelet count (which help fight infection and clotting) are below certain levels (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
AstraZeneca
Registry
clinicaltrials_gov
Start date
1 September 2004
Est. completion
1 February 2007

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇨🇿 Czechia 🇳🇱 Netherlands 🇬🇧 United Kingdom

7 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

To compare Iressa v best supportive care in terms of progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov